393 related articles for article (PubMed ID: 26498038)
1. Clinical detection and categorization of uncommon and concomitant mutations involving BRAF.
Zheng G; Tseng LH; Chen G; Haley L; Illei P; Gocke CD; Eshleman JR; Lin MT
BMC Cancer; 2015 Oct; 15():779. PubMed ID: 26498038
[TBL] [Abstract][Full Text] [Related]
2. Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing.
Lokhandwala PM; Tseng LH; Rodriguez E; Zheng G; Pallavajjalla A; Gocke CD; Eshleman JR; Lin MT
BMC Cancer; 2019 Jul; 19(1):665. PubMed ID: 31277584
[TBL] [Abstract][Full Text] [Related]
3.
Summers MG; Smith CG; Maughan TS; Kaplan R; Escott-Price V; Cheadle JP
Clin Cancer Res; 2017 Jun; 23(11):2742-2749. PubMed ID: 27815357
[No Abstract] [Full Text] [Related]
4. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
Dankner M; Rose AAN; Rajkumar S; Siegel PM; Watson IR
Oncogene; 2018 Jun; 37(24):3183-3199. PubMed ID: 29540830
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Dabrafenib and Trametinib in a Patient with Squamous-Cell Carcinoma, with Mutation p.D594G in
Grenda A; Krawczyk P; Targowska-Duda KM; Kieszko R; Paśnik I; Milanowski J
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674722
[TBL] [Abstract][Full Text] [Related]
6. Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas.
Manca A; Lissia A; Capone M; Ascierto PA; Botti G; Caracò C; Stanganelli I; Colombino M; Sini M; Cossu A; Palmieri G
J Transl Med; 2015 Jan; 13():37. PubMed ID: 25627962
[TBL] [Abstract][Full Text] [Related]
7. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
[TBL] [Abstract][Full Text] [Related]
8. Lymph node metastases of melanoma: challenges for BRAF mutation detection.
Chen G; Dudley J; Tseng LH; Smith K; Gurda GT; Gocke CD; Eshleman JR; Lin MT
Hum Pathol; 2015 Jan; 46(1):113-9. PubMed ID: 25456393
[TBL] [Abstract][Full Text] [Related]
9. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA
Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
[TBL] [Abstract][Full Text] [Related]
10. AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.
Hechtman JF; Sadowska J; Huse JT; Borsu L; Yaeger R; Shia J; Vakiani E; Ladanyi M; Arcila ME
Mol Cancer Res; 2015 Jun; 13(6):1003-8. PubMed ID: 25714871
[TBL] [Abstract][Full Text] [Related]
11. Vemurafenib.
Garbe C; Abusaif S; Eigentler TK
Recent Results Cancer Res; 2014; 201():215-25. PubMed ID: 24756795
[TBL] [Abstract][Full Text] [Related]
12. Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.
Zimmer L; Barlesi F; Martinez-Garcia M; Dieras V; Schellens JH; Spano JP; Middleton MR; Calvo E; Paz-Ares L; Larkin J; Pacey S; Venturi M; Kraeber-Bodéré F; Tessier JJ; Eberhardt WE; Paques M; Guarin E; Meresse V; Soria JC
Clin Cancer Res; 2014 Aug; 20(16):4251-61. PubMed ID: 24947927
[TBL] [Abstract][Full Text] [Related]
13. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
[TBL] [Abstract][Full Text] [Related]
14. Non-p.V600E BRAF Mutations Are Common Using a More Sensitive and Broad Detection Tool.
Carter J; Tseng LH; Zheng G; Dudley J; Illei P; Gocke CD; Eshleman JR; Lin MT
Am J Clin Pathol; 2015 Oct; 144(4):620-8. PubMed ID: 26386083
[TBL] [Abstract][Full Text] [Related]
15. Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report.
Casadevall D; Vidal J; Gallardo F; Zuccarino F; Arumí-Uría M; Dalmases A; Bellosillo B; Montagut C
J Med Case Rep; 2016 Jun; 10(1):158. PubMed ID: 27255157
[TBL] [Abstract][Full Text] [Related]
16. [ Spectrum of oncogene mutations is different in melanoma subtypes].
Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV
Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785
[TBL] [Abstract][Full Text] [Related]
17. BRAF somatic mutations in malignant melanoma and melanocytic naevi.
Thomas NE
Melanoma Res; 2006 Apr; 16(2):97-103. PubMed ID: 16567964
[TBL] [Abstract][Full Text] [Related]
18. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.
Corcoran RB; Atreya CE; Falchook GS; Kwak EL; Ryan DP; Bendell JC; Hamid O; Messersmith WA; Daud A; Kurzrock R; Pierobon M; Sun P; Cunningham E; Little S; Orford K; Motwani M; Bai Y; Patel K; Venook AP; Kopetz S
J Clin Oncol; 2015 Dec; 33(34):4023-31. PubMed ID: 26392102
[TBL] [Abstract][Full Text] [Related]
19. KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma.
Cicenas J; Tamosaitis L; Kvederaviciute K; Tarvydas R; Staniute G; Kalyan K; Meskinyte-Kausiliene E; Stankevicius V; Valius M
Med Oncol; 2017 Feb; 34(2):26. PubMed ID: 28074351
[TBL] [Abstract][Full Text] [Related]
20. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
